

**Accelerating  
neurotechnology  
through investment  
and collaboration**

14th ANNUAL

# NEUROTECH.

## Investing & Partnering Conference

MAY 21-22, 2019 | RENAISSANCE WATERFRONT HOTEL | BOSTON, MA

**FINAL  
WEEKS TO  
REGISTER!**



EVENT SUPPORTER  
 National Institute of  
Neurological Disorders  
and Stroke

## WELCOME

The neurotechnology sector holds promise to deliver treatments for CNS disorders for which the unmet need is high. Over the last decade, significant advances have taken place in this field, driven by venture investment and strategic partnerships. Now in its 14th year, the Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software, and diagnostics for the brain and nervous system.

The conference features keynotes, investor panels, and cutting edge company presentations on a comprehensive selection of neurotech topics. In 2018, the conference drew a full house of over 150 investors and executives for two days of discussion and superb high-level networking.

Companies engaged in this event focus on diverse areas of major unmet need including Alzheimer's, addiction, anxiety, depression, multiple sclerosis, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, Parkinson's, and traumatic injury.

This year's event promises to continue a tradition of carefully curated, high-quality content and invaluable networking. Facilitated networking opportunities and partnering tools provide an ideal venue to connect investors with potential partners and launch the new relationships that will grow into tomorrow's successful treatments and partnerships.


We hope you will join us in our goal of accelerating neurotechnology through investment and collaboration.

**Manage your partnering  
meetings with our online planner**

**Carla Lema Tome**  
Conference Organizer  
Cambridge Healthtech Institute

**DON'T MISS** your opportunity to meet with  
new potential partners at this year's event.

Visit website for additional details.

CORPORATE SPONSOR  neuroscience trials australia

CORPORATE SUPPORT SPONSORS

 premier research

 PsychoGenics  
Accelerating Drug Discovery Through Innovation

## HOTEL & TRAVEL INFORMATION

### Conference Venue and Hotel:

Renaissance Waterfront Hotel  
606 Congress Street | Boston, MA 02210  
Phone: 617-338-4111

**Discounted Room Rate: \$359 s/d**  
**Discounted Room Rate Cut-off Date: April 22, 2019**

**Reservations:** Go to the hotel and venue page  
of [NEUROTECHPartnering.com](http://NEUROTECHPartnering.com)

Organized by  
Cambridge Healthtech Institute

**NEUROTECHPartnering.com**



May 21, 2019  
Tuesday

### 7:30 am Conference Registration and Continental Breakfast

### 8:30 State of the Neurotech Industry

Guest speakers provide an annual review of trends and developments in neurotech.

Speaker: Harry Tracy, President, NI Research

### 9:00 Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Bruce Leutcher, MD, Partner, PJT Partners

Panelists: Jamil Beg, Principal, 5AM Ventures

Laura Tadvalkar, PhD, Senior Associate, MP Health Partners

Deanna Belsky, PhD, Associate, Dolby Family Ventures

Maria Shepherd, Principal, Mass Medical Angels

### 10:00 Coffee Break with Exhibit Viewing

### 10:45 Treatments for Alzheimer's and Cognitive Disorders

As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?

Moderator: Ian N. Kremer, Executive Director, LEAD Coalition (Leaders Engaged on Alzheimer's Disease)

Speakers: Zach Malchano, CEO, Cognito

Martin Tolar, MD, PhD, CEO, Alzheimer

James G. Moe, PhD, MBA, President & CEO, Oligomerix

Michael Szulczewski, President, Gliacure

Susanne Wilke, MBA, PhD, CEO, Cognoptix

### 11:45 Developments on the Horizon for Pain

Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in pain. Hear from leading companies on their approaches.

Moderator: Kerrie Brady, MBA, Chief Business Officer, Executive Vice President, Corporate Strategy, Centrexion

Speakers: Angelique Johnson, PhD, CEO, MEMstim

Philippe Diaz, Co-Founder and CSO, DermaXon

Sunyoung Kim, DPhil, Founder and CEO, ViroMed Co

### 12:45 pm Networking Luncheon

### 2:00 Internal and External Research and Development

Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will be kept in-house or partnered. This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes and platform companies.

Moderator: Michael Kandra, Director, Business Development, Allen Brain Institute

Panelists: Eric Schaeffer, PhD, Senior Director of Neuroscience Innovation, Johnson & Johnson Innovation  
Pierandrea Muglia, MD, Vice President & Head Neuroscience Discovery Medicine, UCB Pharma  
Murall Gopalakrishnan, MBA, PhD, Senior Director & Global Head, Search & Evaluation Neuroscience

### 3:00 Refreshment Break with Exhibit Viewing

### 3:30 Targeting Orphan Diseases

Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more.

Moderator: Nicole Johnson, Founder, FOXG1 Research Foundation

Speakers: Lynn Durham, CEO & Founder, Stalicia

Sean Ekins, PhD, Founder and CEO, Collaborations

Pharmaceuticals

Sylvain Lengacher, PhD, CEO & Co-Founder, GliaPharm

Anthony R. DePasqua, MBA, Co-Founder and CEO, EnClear

Jim DeMesa, MD, MBA, CEO, Emerald Health

Pharmaceuticals

### 4:30 Strategic Development of Your Product Outside of the US: The Australian Advantage

Sponsored by  
neuroscience trials australia

Tina Soulis, PhD, CEO, Neuroscience Trials Australia

### 4:45 Emerging Company Showcase

The fourth annual Emerging Company Showcase offers the stage to young neurotech companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field. Please view the event website for a full list of this year's presenters.

### 5:30 Welcome Reception with Exhibit Viewing

### 6:30 Close of Day

# Be Part of the Global Collaboration

## COUNTRIES REPRESENTED:



USA



Canada



Japan



Spain



Germany



Finland



Israel

## WHAT YOU CAN EXPECT IN BOSTON\*

**80%** of attendees are  
Director/VP/C-level and above



**75%** of conference attendees used the online partnering tool to conduct onsite meetings

**630+** Meeting Requests

**200+** Confirmed Meetings

**150+** participants in Boston

\* At past Neurotech Events

May 22, 2019  
Wednesday

### 8:00 am Continental Breakfast

### 8:30 KEYNOTE PRESENTATION

#### Translating Neurotechnology from the Lab to the Clinic

John Donoghue, PhD, Director, Wyss Center for Bio and Neuroengineering

### 9:00 Partnering and Licensing in Neurotech Panel

Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics, and what they look for in a partner.

Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises

Panelists: Atsushi Hashimoto, Director, Business Development, Mitsubishi Tanabe Pharma  
Robert Bagdorf, MD, MBA, Vice President, Global Business Development, Pfizer

Nicholas Scarchilli, Director, Business Development, Biogen

### 10:00 Coffee Break with Exhibit Viewing

### 10:45 Next Generation Psychiatry

Sponsored by  
  
PsychoGenics  
Leading the way in brain science

Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging. Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.

Moderator: Manuel Lopez Figueroa, PhD, Managing Director, Bay City Capital

Speakers: David Baker, COO and Acting CEO, Vallon Pharma

Ekaterina Malievskaia, MD, MSc, CMO and Co-Founder, Compass Pathways

Teresa Tarrago, PhD, CEO and Co-Founder, iProteos  
Emer Leahy, PhD, MBA, President and CEO, Psychogenics

### 11:45 Frontiers in Neurotechnology

In this session we will hear from companies on the cutting edge. Artificial Intelligence (AI) applications, novel neurostimulation devices developed for new markets, closed loop systems create the promise of reduced side

effects and more targeted treatment. New technology is yielding benefits in discovery and delivery of therapeutics to brain. This session will preview of next generation products and companies in neurotechnology.

Moderator: Aaron Sandoski, Co-Founder and Managing Director, Norwich Ventures

Speakers: Alice Zhang, CEO, Verge Therapeutics  
Bob Cathcart, President and CEO, AIM Medical Robotics

Philip G Ashton-Rickardt, PhD, Founder and CEO, Smith Therapeutics

### 12:45 pm Networking Luncheon

### 2:00 Parkinson's and Other Movement Disorders

Current treatments for movement disorders can improve functioning but suffer from side effects and "off" periods, especially as the disease progresses. A number of novel pipeline pharmaceuticals and devices seek to address these issues. This session will explore how disease-modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcome for patients.

Moderator: Wasim Q. Malik, PhD, Managing Partner, Iaso Ventures

Speakers: Adrien Chatillon, CEO, ActiPulse  
Randall Moreadith, MD, PhD, President and CEO, Serina Therapeutics

Susan Rosenbaum, JD, Founder, Chairman and CEO, Lauren Sciences

### 3:00 New Discoveries powered by NINDS

The small business program at NINDS is used to achieve the mission of the Institute by supporting innovative ideas at different stages of development, including applied bench research, translational research, and early stage clinical trials.


Moderator: Stephanie Fertig, Director, NINDS Small Business Programs

Speakers: Michael A Tones, PhD, Head of Pharmacology, Pulse Therapeutics

Sherine Chan, PhD, Co-Founder, Neuroene Therapeutics  
Thomas Sanderson, Co-Founder, Mitovation

### 4:00 Close of Conference

## 2018 Conference Attendee Geographic Breakdown




### DELEGATE TITLE

- Executive 58%
- Director 15%
- Manager 4%
- Scientist/Technologist 5%
- Sales & Marketing 12%
- Assistant 4%
- Other 3%


### COMPANY TYPE

- Academic 5%
- Biotechnical 49%
- Commercial 3%
- CRO 7%
- Financial 12%
- Government 2%
- Healthcare 5%
- Healthcare Provider 2%
- Other 9%
- Pharmaceutical 6%



### GEOGRAPHIC REGION

- USA 80%
- France 12%
- Australia 2%
- Israel 2%
- Japan 2%
- Switzerland 2%



HOW TO REGISTER:

NEUROTECH

NEUROTECHPartnering.com

Investing & Partnering  
Conference

MAY 21-22, 2019  
BOSTON, MA  
Renaissance  
Waterfront Hotel